Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth potential while failing to meet revenue expectations, leading to a significant drop in stock price [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 9, 2024, to May 8, 2025 [3]. - Allegations include that Iovance made overwhelmingly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [3]. Financial Performance and Stock Impact - On July 25, 2024, Iovance announced disappointing financial results for Q2 2024 and reduced its revenue guidance for the full fiscal year 2024 [3]. - Contributing factors to the lowered guidance included maintenance of the iCTC, lower than expected Proleukin sales, and a variable pace of treatment initiation at approved centers [3]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case [4]. Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investor rights against deceit and fraud [5].

Core Viewpoint - The article discusses a class action lawsuit against Krispy Kreme, Inc. (NASDAQ: DNUT) due to allegations of misleading statements regarding the demand for its products at McDonald's locations, which negatively impacted the company's stock performance [1][3]. Summary by Sections Allegations - The complaint alleges that Krispy Kreme's management provided overly positive statements while concealing material adverse facts about declining demand at McDonald's locations, which contributed to a decrease in average weekly sales per store [3]. - The partnership with McDonald's was reportedly unprofitable, leading Krispy Kreme to pause its expansion into new locations [3]. Financial Performance - On February 25, 2025, Krispy Kreme reported disappointing fourth quarter 2024 results, with net revenue of $404 million, a decline of 10.4%, and a decrease in average sales per door per week due to a changing customer mix [3]. - Following this announcement, the stock price fell from $9.13 per share on February 24, 2025, to $7.13 per share on February 25, 2025 [3]. - On May 8, 2025, the company reported first quarter 2025 net revenue of $375.2 million, a decline of 15.3% or $67.5 million, and announced a reassessment of its deployment schedule with McDonald's [3]. - The stock price dropped from $4.33 per share on May 7, 2025, to $3.26 per share on May 8, 2025, marking a decline of about 25% in one day [3]. Next Steps for Shareholders - Shareholders who purchased DNUT shares during the specified class period are encouraged to register for the class action by July 15, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=155074&from=3 CLASS PERIOD: October 31, 2024 to Apri ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DoubleVerify Holdings, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from November 10, 2023, to February 27, 2025 [1][3]. Allegations - The complaint alleges that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited, impacting its competitive position against platforms like Meta and Amazon [3]. - It is claimed that DoubleVerify's ability to monetize its Activation Services was constrained due to the high costs and time required for technology development for closed platforms, which were not adequately disclosed to investors [3]. - The lawsuit states that monetization of DoubleVerify's Activation Services on certain closed platforms would take several years, contrary to what was communicated to shareholders [3]. - Competitors were reportedly better positioned to integrate AI into their offerings on closed platforms, negatively affecting DoubleVerify's competitiveness and profitability [3]. - The company allegedly overbilled customers for ad impressions served to bots, which were known to operate from data center server farms [3]. - The risk disclosures provided by DoubleVerify were claimed to be materially false and misleading, as they downplayed already materialized adverse facts [3]. - As a result of these issues, the positive statements made by the defendants regarding the company's business and prospects were deemed materially false or misleading [3]. Next Steps for Shareholders - Shareholders who purchased shares of DoubleVerify during the specified class period are encouraged to register for the class action by July 21, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=155065&from=3 CLASS PERIOD: June 22, 2 ...

Misty, I I wonder what leverage and how this changes those civil claims because he is facing a mountain of civil claims. It felt like they were coming fast and furious there after he got indicted on the federal charges, the criminal charges, then the civil deluge of lawsuits started to come out. Does this change the calculation on the civil side at all.Does it help him. What do you think it the effect might be. So certainly there were so many civil lawsuits it was hard for us to even keep up.They were filed ...

Judge Says $4 Billion Celsius Lawsuit Against Tether Can Proceed► https://t.co/EtYAxrp61g https://t.co/EtYAxrp61g ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified Class Period of the upcoming lead plaintiff deadline on July 8, 2025, and the potential for compensation without out-of-pocket fees [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Digimarc Corporation, and investors who wish to serve as lead plaintiff must act by July 8, 2025 [2]. - The lawsuit alleges that Digimarc made false and misleading statements regarding its business operations, specifically about a large commercial partner not renewing a significant contract, which adversely affected subscription and annual recurring revenue [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3].

LOS ANGELES, July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Fortrea Holdings, Inc. ("Fortrea" or "the Company") (NASDAQ: FTRE) for violations of the federal securities laws.Shareholders who purchased the Company's securities between July 3, 2023 and February 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 1, 2025. DJS Law Group CASE DETAILS:  The complaint alleges that the Company made false and misleading s ...

[Music] [Applause] Yeah, that's a six-year-old me, a young man that had no idea what life's journey was all about and how precious it actually is. If you don't mind, I'd like to read a short short poem uh that I made shortly after my first suicide attempt. It's entitled I'm just a number. I'm just a number. I breathe. I seek. I blunder. I'm just a number. I fall. I hurt. I wonder. I'm just a number. I've loved. I've lived. I'll die. But Lord knows I've tried to be more than just a number. In 1984, I was an ...